ENDRA Life Sciences Inc.

NDRA • Medical - Diagnostics & Research

$6.05

— 0.00 (0.00%)

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$14.98M

Crecimiento

-100.0%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.22Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 14 ago 2026, 1:12 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$6.05

Change0.00%

Shares Out2.48M

Market Cap$14.98M

Enterprise Value$13.66M

52W Range2.96 - 9.85

Beta-0.07

P/E-2.53

P/B2.37

P/FCF-1.87

EV/EBITDA-2.71

EV/FCF-1.71

Price$6.05

Change0.00%

Shares Out2.48M

Market Cap$14.98M

Enterprise Value$13.66M

52W Range2.96 - 9.85

Beta-0.07

P/E-2.53

P/B2.37

P/FCF-1.87

EV/EBITDA-2.71

EV/FCF-1.71

Earnings Yield-39.51%

FCF Yield-53.48%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.22

Current Ratio1.29

Quick Ratio1.29

Revenue 5Y-100.00%

Volume6.83K

Avg Volume27.29K

EPS Surprise0.14

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

67/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

90/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.22Rentabilidad débil

Analyst view

Analyst sentiment and price target

NDRA

Analyst sentiment

Based on 4 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 6/30/2017

Industria: Medical - Diagnostics & Research

P/B i: 2.37

Deuda / Patrimonio i: 0.22

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje13 / 20

Deuda / Patrimonio: 0.22

Ratio corriente: 1.29

Ratio rápido: 1.29

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Jacroux Richard

Transacción: 03/02/2026

COMPRA

Cambio

+13,461

Precio

Not reported

Presentación

03/04/2026

Tipo

COMPRA

Tokman Alexander Y

Transacción: 03/02/2026

COMPRA

Cambio

+26,921

Precio

Not reported

Presentación

03/04/2026

Tipo

COMPRA

Tokman Alexander Y

Transacción: 01/21/2026

COMPRA

Cambio

+75,000

Precio

Not reported

Presentación

01/23/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Jacroux Richard	COMPRA	+13,461	Not reported	03/02/2026	03/04/2026
Tokman Alexander Y	COMPRA	+26,921	Not reported	03/02/2026	03/04/2026
Tokman Alexander Y	COMPRA	+75,000	Not reported	01/21/2026	01/23/2026
Basenese Lou	COMPRA	+60,324	Not reported	01/21/2026	01/23/2026
Jacroux Richard	COMPRA	+20,000	Not reported	01/21/2026	01/23/2026
Harsh Michael	COMPRA	+60,324	Not reported	01/21/2026	01/23/2026
DIGIANDOMENICO ANTHONY	COMPRA	+60,324	Not reported	01/21/2026	01/23/2026
DIGIANDOMENICO ANTHONY	COMPRA	+70,822	$7.06	10/10/2025	10/15/2025
DIGIANDOMENICO ANTHONY	COMPRA	+141,644	$6.81	10/10/2025	10/15/2025
DIGIANDOMENICO ANTHONY	COMPRA	+5,384	Not reported	06/11/2025	07/01/2025
Harsh Michael	COMPRA	+5,384	Not reported	06/11/2025	07/01/2025
Basenese Lou	COMPRA	+5,384	Not reported	06/11/2025	07/01/2025
UBS Group AG	COMPRA	0	Not reported	08/27/2024	09/05/2024
UBS Group AG	OPCIÓN	0	Not reported	08/27/2024	08/29/2024
Jacroux Richard	OTRO	0	Not reported	08/08/2024	08/15/2024
Tokman Alexander Y	COMPRA	+600	$1.59	01/02/2024	02/23/2024
DIGIANDOMENICO ANTHONY	COMPRA	+600	$1.59	01/02/2024	02/23/2024
Harsh Michael	COMPRA	+600	$1.59	01/02/2024	02/23/2024
Basenese Lou	COMPRA	+600	$1.59	01/02/2024	02/23/2024
Thornton Michael Milos	COMPRA	+15,000	$1.65	05/18/2023	05/22/2023

Sobre la compañía

ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.

Fuente - Link

Competidores

BBLG BGMS BNBX DHAI GCTK HSCS ISPC MOVE NAOV VERO

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), reported financial results for the quarter ended June 30, 2026, and provided a business update. Second Quarter 2026 and Recent Highlights On June 25, 2026, ENDRA entered into a definitive merger agreement with ASP Isotopes Inc. (NASDAQ: ASPI), Noble Africa LLC (“Noble Africa”), R.

Business Wire

ASP Isotopes Issues Letter to Shareholders

DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASP Isotopes”, “ASPI” or the “Company”), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, today released the following letter to shareholders from its Executive Chairman and Chief Executive Officer, Paul Mann. Dear Fellow Shareholder, As we prepare to announce financial results for the second quarter of 2026, I wanted to take this opportunity to update you on the developments taking place at ASP Isotopes Inc. All of our business units are making considerable progress, group revenues are increasing, and three of our business units appear at an inflection point and are expected to make substantial contributions to achieving profitability in the near term: During 1H 2026, our global PET Labs group demonstrated organic revenue growth of over 50% as compared to 1H 2025.

GlobeNewsWire

Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company

DALLAS & ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes" or “ASPI”), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, and ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or “NDRA”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that RedChip Companies will host an investor webi.

Business Wire

Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company

Noble Africa was created to unlock the value of Renergen's Virginia Gas Project through a public company focused on helium and LNG Learn why the Virginia Gas Project is positioned to become one of the world's most strategic helium developments as global supply tightens and demand accelerates DALLAS, TX AND ANN ARBOR, MI / ACCESS Newswire / July 17, 2026 / ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or "ASPI"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, and ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or "NDRA"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that RedChip Companies will host an investor webinar featuring Noble Africa, a wholly owned subsidiary of ASP Isotopes and the holding company for Renergen Limited, on Tuesday, July 21, 2026, at 4:15 p.m. ET. The webinar will highlight Noble Africa's proposed merger (the "Proposed Merger" and, together with the related transactions, the "Proposed Transactions") with ENDRA, which, if completed, is expected to result in Noble Africa becoming a Nasdaq-listed public company trading under the ticker symbol "NOBA.

Accesswire

Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-18	-1.23	-1.09	0.14
2026-03-31	-1.23	-3.26	-2.03
2025-11-14	-1.95	-1.75	0.2
2025-08-14	-2.27	-1.71	0.56
2025-05-15	-3.91	-2.59	1.32
2025-03-31	-4.1	-9.4	-5.3
2024-11-15	-62.3	-5.85	56.45
2024-08-22	-122.5	-139.86	-17.36
2024-05-14	-0.27	-454.55	-454.28
2024-03-28	-0.36	-297.2	-296.84
2023-11-14	-0.43	-699.3	-698.87
2023-08-14	-0.55	-751.75	-751.2